<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of Candida infection in neonates
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of Candida infection in neonates
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of Candida infection in neonates
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mohan Pammi, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karen M Puopolo, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Candida
         </em>
         is an important cause of neonatal infections and is associated with significant morbidity and mortality, especially in extremely low and very low birth weight infants (defined as birth weights &lt;1000 g and &lt;1500 g, respectively). Successful management of neonatal candidiasis includes appropriate antifungal therapy and supportive care, as well as preventive measures to reduce the risk of systemic candidal infections.
        </p>
        <p>
         The treatment of
         <em>
          Candida
         </em>
         infections in neonates will be reviewed here. The clinical manifestations, diagnosis, etiology, risk factors, and prevention of neonatal candidal infections are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5024.html" rel="external">
          "Clinical manifestations and diagnosis of Candida infection in neonates"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5028.html" rel="external">
          "Epidemiology and risk factors for Candida infection in neonates"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5042.html" rel="external">
          "Prevention of Candida infection in neonates"
         </a>
         .)
        </p>
        <p>
         In addition, the treatment of breastfeeding mothers with candidal skin infections is also presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4996.html" rel="external">
          "Common problems of breastfeeding and weaning", section on 'Candidal infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3579458722">
         <span class="h1">
          MANAGEMENT APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of candidal infections in neonates is based on the type and severity of infection, as discussed in the following sections. There are two broad categories of candidal infections in neonates:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Noninvasive mucocutaneous candidiasis (eg, thrush, diaper dermatitis) (see
         <a class="local">
          'Mucocutaneous candidiasis'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Invasive infections (which can involve the bloodstream, urinary tract, central nervous system [CNS], and other focal sites) (see
         <a class="local">
          'Invasive infection'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Our management approach is generally consistent with the recommendations of the Infectious Diseases Society of America and the American Academy of Pediatrics [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2039610105">
         <span class="h2">
          Mucocutaneous candidiasis
         </span>
        </p>
        <p class="headingAnchor" id="H1211767987">
         <span class="h3">
          Low risk of systemic infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonates with noninvasive mucocutaneous candidiasis (ie, thrush, diaper dermatitis) are generally at low risk of disseminated systemic infection and can be treated with topical antifungal therapy.
        </p>
        <p>
         Risk factors for invasive candidiasis are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5028.html" rel="external">
          "Epidemiology and risk factors for Candida infection in neonates", section on 'Risk factors for invasive candidiasis'
         </a>
         .)
        </p>
        <p>
         Appropriate topical antifungal agents for noninvasive mucocutaneous candidiasis include
         <a class="drug drug_pediatric" data-topicid="12654" href="/z/d/drug information/12654.html" rel="external">
          nystatin
         </a>
         and azole topical preparations. Systemic antifungal agents are used only if the infection is refractory to topical therapy. When systemic therapy is deemed necessary,
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         (3 mg/kg once a day for seven days) is our preferred agent in most cases because it is well tolerated and effective in neonates [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Fluconazole'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2432.html" rel="external">
          "Oropharyngeal candidiasis in adults", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H609008812">
         <span class="h4">
          Oral candidiasis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Whom to treat
         </strong>
         – In healthy term infants who lack symptoms, are feeding well, and are at low risk of invasive candidiasis, oral candidiasis may not require treatment. Data concerning treatment in this setting are lacking and the optimal approach is uncertain. Some experts prefer to treat all infants, including low-risk and asymptomatic neonates. Whereas some guidelines suggest treating thrush in this setting only if there are symptoms (eg, feeding difficulties, maternal breast pain) [
         <a href="#rid4">
          4
         </a>
         ]. Breastfed dyads can develop a cycle of breast infection in the mother accompanied by oral thrush in the infant, with the infection repeatedly being transferred from one to the other. Simultaneous treatment of both may break this cycle. (See
         <a class="medical medical_review" href="/z/d/html/4996.html" rel="external">
          "Common problems of breastfeeding and weaning", section on 'Candidal infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of agent
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12654" href="/z/d/drug information/12654.html" rel="external">
          Nystatin
         </a>
         , a polyene topical antifungal agent, is our preferred initial agent to treat oral candidiasis (thrush) as it is not absorbed systemically from the gastrointestinal tract. It is administered as an oral suspension (100,000 units/mL) at a dose of 0.5 mL to each side of the mouth four times a day between feeds for 5 to 10 days. Reported cure rates with oral nystatin suspension range from 29 to 85 percent [
         <a href="#rid3">
          3,5
         </a>
         ]. Oral
         <a class="drug drug_pediatric" data-topicid="16825" href="/z/d/drug information/16825.html" rel="external">
          miconazole
         </a>
         gel (not available in the United States) has a better cure rate (&gt;90 percent), but systemic absorption may occur and gastrointestinal side effects are reported in 6 percent of premature neonates [
         <a href="#rid5">
          5
         </a>
         ]. Neonates with inadequate response to topical nystatin can be treated with oral
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         (3 mg/kg once a day for seven days).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of reinfection
         </strong>
         – Measures to prevent reinfection include sterilization or decolonization of items that are placed in the infant's mouth (eg, bottle nipples and pacifiers).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1941173628">
         <span class="h4">
          Diaper dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diaper dermatitis is treated with topical
         <a class="drug drug_pediatric" data-topicid="12654" href="/z/d/drug information/12654.html" rel="external">
          nystatin
         </a>
         or azole cream (eg,
         <a class="drug drug_pediatric" data-topicid="16825" href="/z/d/drug information/16825.html" rel="external">
          miconazole
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13173" href="/z/d/drug information/13173.html" rel="external">
          clotrimazole
         </a>
         cream) [
         <a href="#rid5">
          5
         </a>
         ]. Nystatin usually is effective and is generally the least expensive option. (See
         <a class="medical medical_review" href="/z/d/html/5795.html" rel="external">
          "Diaper dermatitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3724996816">
         <span class="h3">
          High risk of systemic infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with mucocutaneous candidiasis with a high likelihood of systemic infection (eg, congenital cutaneous candidiasis [CCC], invasive dermatitis), we suggest initiating systemic antifungal therapy while awaiting the results of blood and other cultures. A full evaluation should be performed to determine the extent of dissemination, which informs the duration of therapy. (See
         <a class="local">
          'Evaluation for extent of dissemination'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H670454570">
         <span class="h4">
          Congenital cutaneous candidiasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on limited data, we suggest systemic antifungal therapy for neonates with CCC [
         <a href="#rid6">
          6,7
         </a>
         ]. For premature infants and infants with complicated infection (clinical signs of sepsis or respiratory distress), amphotericin B is appropriate therapy [
         <a href="#rid6">
          6
         </a>
         ]. Term infants who are tolerating feeds can be treated with oral
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         . (See
         <a class="local">
          'Amphotericin B'
         </a>
         below and
         <a class="local">
          'Fluconazole'
         </a>
         below.)
        </p>
        <p>
         Neonates with CCC are at risk for dissemination to the bloodstream, urine, or cerebrospinal fluid (CSF). CCC occurs most commonly in low birth weight, preterm infants, but it can also affect term infants. The risk of dissemination is greatest in extremely low birth weight (ELBW; birth weight &lt;1000 g) infants [
         <a href="#rid6">
          6,7
         </a>
         ]. In a retrospective case series of 21 infants with CCC (18 preterm and 3 term; mean birth weight 950 g), all but one infant were treated with systemic antifungal therapy within 48 hours of rash presentation. Disseminated infection occurred in two infants (one was the infant in whom systemic antifungal therapy was delayed; the other presented shortly after birth with disseminated infection) [
         <a href="#rid7">
          7
         </a>
         ]. There was only one death in this series (the infant with early disseminated disease). These data provide limited evidence that prompt systemic therapy may reduce the risk of systemic infection and mortality. Earlier reports indicated that systemic infection developed in up to two-thirds of ELBW neonates with CCC, with mortality rates of up to 40 percent [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1187720629">
         <span class="h3">
          Invasive fungal dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Invasive fungal dermatitis is a condition that is unique to ELBW infants (birth weight &lt;1000 g) during the first two weeks after birth. Most affected patients have evidence of disseminated fungal disease. Thus, we suggest initiating systemic therapy with amphotericin B while awaiting culture results. (See
         <a class="local">
          'Amphotericin B'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5024.html" rel="external">
          "Clinical manifestations and diagnosis of Candida infection in neonates", section on 'Invasive fungal dermatitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Invasive infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of neonates with invasive
         <em>
          Candida
         </em>
         infection, including bloodstream, urinary tract, CNS, and/or other invasive focal infection, involves the following components [
         <a href="#rid1">
          1,2,8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation to assess the extent of dissemination. (See
         <a class="local">
          'Evaluation for extent of dissemination'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Removal of any source of infection (eg, central venous catheter [CVC], urinary catheter). (See
         <a class="local">
          'Catheter-associated candidemia'
         </a>
         below and
         <a class="local">
          'Urinary tract infection'
         </a>
         below and
         <a class="local">
          'Persistent infection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of systemic antifungal agents. Amphotericin B is the preferred drug for the treatment of most systemic neonatal candidal infections. (See
         <a class="local">
          'Systemic antifungal agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3415034306">
         <span class="h3">
          Evaluation for extent of dissemination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants who are diagnosed with
         <em>
          Candida
         </em>
         infection involving the bloodstream, urinary tract, CNS, eyes, heart valves, bone, or joints should undergo evaluation for systemic disseminated infection, which informs management decisions. The following tests should be performed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cultures of the blood, urine, and CSF
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dilated eye examination to evaluate for endophthalmitis  (
         <a class="graphic graphic_picture graphicRef58685" href="/z/d/graphic/58685.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Echocardiography to assess for cardiac thrombi or vegetations
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ultrasonography of the liver, spleen, kidneys, and bladder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Head ultrasound
        </p>
        <p>
        </p>
        <p>
         The diagnostic approach is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5024.html" rel="external">
          "Clinical manifestations and diagnosis of Candida infection in neonates", section on 'Evaluation for extent of dissemination'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H251015114">
         <span class="h3">
          Catheter-associated candidemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For catheter-associated candidemia without evidence of dissemination, we suggest treatment with amphotericin B (1 mg/kg per dose given intravenously [IV] once daily) and removal of the CVC. The duration of therapy is typically 14 days from the first negative culture. (See
         <a class="local">
          'Amphotericin B'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          Fluconazole
         </a>
         (12 mg/kg given IV once daily) is an acceptable alternative for susceptible isolates. (See
         <a class="local">
          'Fluconazole'
         </a>
         below and
         <a class="local">
          'Therapy based on susceptibility'
         </a>
         below.)
        </p>
        <p>
         In addition to systemic antifungal therapy, the CVC should be removed as soon as possible. The CVC serves as a focus for
         <em>
          Candida
         </em>
         , and removing it helps to clear the infection. In a retrospective study of 104 neonates with CVC-associated candidemia cared for in the neonatal intensive care unit setting, early removal of the CVC (within three days of the first positive blood culture) was associated with shorter duration of candidemia (median of three versus six days) and lower mortality (0 versus 39 percent) compared with late CVC removal (&gt;3 days after first positive culture) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3050552793">
         <span class="h3">
          Urinary tract infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For treatment of
         <em>
          Candida
         </em>
         urinary tract infections (UTIs), we suggest amphotericin B (1 mg/kg per dose IV once daily) for 10 to 14 days. In addition, the urinary catheter, if present, should be removed. As with CVCs, the urinary catheter serves as a focus for
         <em>
          Candida
         </em>
         and removing it helps to clear the infection. (See
         <a class="local">
          'Amphotericin B'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          Fluconazole
         </a>
         (12 mg/kg given orally or IV once daily) is an acceptable alternative for susceptible isolates. Isolated uncomplicated UTI can be treated with oral fluconazole if the infant is clinically stable and tolerating feeds. IV fluconazole is preferred for complicated UTIs (eg, associated with fungal mass). (See
         <a class="local">
          'Fluconazole'
         </a>
         below and
         <a class="local">
          'Therapy based on susceptibility'
         </a>
         below.)
        </p>
        <p>
         As previously discussed, ultrasonography of the bladder and kidneys should be performed to determine if there is renal parenchymal infiltration, calyceal mycetoma, or fungal masses in the urinary tract (see
         <a class="local">
          'Evaluation for extent of dissemination'
         </a>
         above). If a renal fungal mass is seen on ultrasonography, we typically continue treatment until there is complete resolution of the fungal abscess or mass by imaging. Though some studies suggest that ultrasonography correlates poorly with the course of the infection and patient outcome [
         <a href="#rid10">
          10,11
         </a>
         ], we continue to use ultrasonography to guide duration of therapy because alternative diagnostic/prognostic tools are not available. The clinical status of the patient is also an important consideration in determining the duration of treatment.
        </p>
        <p class="headingAnchor" id="H3044461313">
         <span class="h3">
          Central nervous system infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most neonates with
         <em>
          Candida
         </em>
         CNS infection, we suggest amphotericin B monotherapy (1 mg/kg per dose IV once daily) [
         <a href="#rid2">
          2
         </a>
         ]. Therapy continues for at least three weeks and should be continued until clinical signs, CSF abnormalities, and radiographic abnormalities (if present) have resolved. (See
         <a class="local">
          'Amphotericin B'
         </a>
         below.)
        </p>
        <p>
         CNS devices (eg, shunts and ventriculostomy drains), if present, should be removed if possible [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         If the CSF does not become sterile within a few days or if the patient's clinical status deteriorates despite treatment with amphotericin B monotherapy,
         <a class="drug drug_pediatric" data-topicid="13304" href="/z/d/drug information/13304.html" rel="external">
          flucytosine
         </a>
         (25 mg/kg per dose given orally every six hours) can be added to the regimen [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="local">
          'Flucytosine'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2592346812">
         <span class="h3">
          Disseminated disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For neonates with disseminated disease, we suggest amphotericin B (1 mg/kg per dose IV once daily). (See
         <a class="local">
          'Amphotericin B'
         </a>
         below.)
        </p>
        <p>
         Monotherapy with
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         (12 mg/kg given IV once daily) is an acceptable alternative for susceptible isolates if CNS infection has been excluded and the course is otherwise uncomplicated. (See
         <a class="local">
          'Fluconazole'
         </a>
         below and
         <a class="local">
          'Therapy based on susceptibility'
         </a>
         below.)
        </p>
        <p>
         The optimal duration of therapy is unclear. Our approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uncomplicated candidemia without focal infection
         </strong>
         – Based upon the limited available data, we treat neonates with uncomplicated candidemia (ie, without a focal infection) for a minimum of 14 days after the first sterile blood culture and resolution of signs attributable to candidemia [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CNS infection
         </strong>
         – Treatment for
         <em>
          Candida
         </em>
         CNS infection should be administered for at least three weeks and until all clinical signs, CSF abnormalities, and CNS imaging abnormalities have resolved. (See
         <a class="local">
          'Central nervous system infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complicated candidemia associated with focal infection
         </strong>
         – Candidemia associated with focal infections (eg, endocarditis, renal fungal masses) is often persistent and/or difficult to eradicate. Prolonged therapy is generally warranted in these infants (usually four to six weeks). Surgical removal of the foci may also be necessary in some cases [
         <a href="#rid1">
          1
         </a>
         ]. The duration of therapy is individualized based upon sterilization of blood cultures, resolution of clinical signs, and resolution of imaging findings.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H707761728">
         <span class="h3">
          Persistent infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In instances where clearance of candidemia is not observed after primary treatment with amphotericin B, a second agent (eg,
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         or an echinocandin) is added. There is a paucity of evidence to guide the best combination therapy in such neonatal cases [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Fluconazole'
         </a>
         below and
         <a class="local">
          'Echinocandins'
         </a>
         below.)
        </p>
        <p>
         All potentially contaminated indwelling foreign material should be removed (eg, CVCs, urinary catheters, ventriculostomy drains). Surgical resection of infected tissue may be needed if systemic antifungal therapy is not successful in eradicating the infection or if the infected tissue causes functional impairment. Functional impairment may be seen in patients with a fungal mass causing urinary obstruction or hemodynamic compromise of the right atrium [
         <a href="#rid13">
          13-16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2006703050">
         <span class="h3">
          Therapy based on susceptibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients with positive cultures, the
         <em>
          Candida
         </em>
         species and its susceptibility to antifungal agents should be determined. Based upon the results, the choice of antifungal agent can be modified, if appropriate. If the species is susceptible to amphotericin B, monotherapy is the preferred choice of therapy.
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          Fluconazole
         </a>
         is an alternative agent for susceptible isolates.
        </p>
        <p>
         Although amphotericin B is effective for treating most neonatal invasive
         <em>
          Candida
         </em>
         infections, there are reports of systemic infections with
         <em>
          Candida
         </em>
         species that are refractory (eg,
         <em>
          Candida
         </em>
         <em>
          glabrata
         </em>
         and
         <em>
          Candida
         </em>
         <em>
          krusei
         </em>
         ) or resistant (eg,
         <em>
          Candida
         </em>
         <em>
          lusitaniae
         </em>
         ) to amphotericin B. (See
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          SYSTEMIC ANTIFUNGAL AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The four different classes of antifungal agents used to treat invasive neonatal candidiasis are [
         <a href="#rid17">
          17
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyenes – Polyenes include
         <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">
          amphotericin B deoxycholate
         </a>
         , which is the preferred antifungal agent for most invasive neonatal
         <em>
          Candida
         </em>
         infections [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="local">
          'Amphotericin B'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triazoles – The most commonly used triazole in neonates is
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         . It is an alternative to amphotericin B in some infants if the isolate is susceptible. (See
         <a class="local">
          'Fluconazole'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nucleoside analogues – The most commonly used nucleoside analogue in neonates is
         <a class="drug drug_pediatric" data-topicid="13304" href="/z/d/drug information/13304.html" rel="external">
          flucytosine
         </a>
         . It is sometimes used in combination with amphotericin B in neonates with central nervous system (CNS) infections. (See
         <a class="local">
          'Flucytosine'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Echinocandins – Echinocandins include
         <a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="130086" href="/z/d/drug information/130086.html" rel="external">
          anidulafungin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">
          micafungin
         </a>
         . These drugs are not routinely used for neonatal
         <em>
          Candida
         </em>
         infections. (See
         <a class="local">
          'Echinocandins'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Amphotericin B
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">
          Amphotericin B deoxycholate
         </a>
         is the preferred drug for treatment of most systemic neonatal
         <em>
          Candida
         </em>
         infections [
         <a href="#rid2">
          2
         </a>
         ]. Most
         <em>
          Candida
         </em>
         species are susceptible to amphotericin B, and this drug is efficacious and well tolerated in neonates [
         <a href="#rid2">
          2,18-20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2329631167">
         <span class="h3">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amphotericin B is administered intravenously (IV) at a dose of 1 mg/kg every 24 hours [
         <a href="#rid2">
          2,19
         </a>
         ]. After completing one week of therapy with daily dosing, therapeutic serum concentrations can be maintained by administering 1.5 mg/kg per dose IV every other day; however, this practice is not routine [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The dose of amphotericin B generally does not need be adjusted in patients with preexisting renal insufficiency. However, if there is renal toxicity thought to be drug related, the dose should be reduced (either by using alternate-day dosing or reducing the daily dose by 50 percent).
        </p>
        <p>
         An initial test dose (sometimes given to children and adults receiving amphotericin B) is
         <strong>
          not
         </strong>
         necessary in infants, because of the lower rate of infusion-related side effects. (See
         <a class="local">
          'Side effects'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse effects of amphotericin appear to be less common and less severe in neonates than in older children and adults. Although there is a potential for nephrotoxicity and hypokalemia due to renal losses, it appears that most infants display no or only transient nephrotoxicity [
         <a href="#rid21">
          21
         </a>
         ]. This was illustrated in a retrospective review of 92 infants &lt;90 days of age (median gestational age 26 weeks) who received at least three doses of amphotericin [
         <a href="#rid22">
          22
         </a>
         ]. Nephrotoxicity (defined as an increase in serum creatinine of 0.4 mg/dL) developed in 16 percent of patients, though maximum creatinine values did not exceed 2 mg/dL. In addition, 17 percent developed hypokalemia (defined as serum potassium &lt;3 mEq/L), which was more likely in patients with nephrotoxicity. By the end of amphotericin therapy, creatinine levels returned to baseline in eight patients, were decreasing in three patients, and remained elevated in four patients. Amphotericin therapy was not discontinued, and there was no dose reduction in any of the patients. There was no difference between infants who did or did not develop nephrotoxicity in terms of gestational age, birth weight, sex, underlying medical conditions, use of other potentially nephrotoxic medications or amphotericin exposure, and duration of therapy.
        </p>
        <p>
         Other reported adverse effects include hypomagnesemia caused by excessive renal losses, bone marrow suppression with anemia and thrombocytopenia, and an increase in hepatic enzymes. These abnormalities are infrequent, dose dependent, and resolve with cessation of the drug.
        </p>
        <p class="headingAnchor" id="H3407081215">
         <span class="h3">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the potential adverse effects, infants receiving amphotericin B should have regular laboratory monitoring. In our practice, we monitor the following laboratory studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolytes (including potassium and magnesium) daily or every other day
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum creatinine daily or every other day initially and, if stable, testing can be spaced to twice weekly
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count with differential and platelet count twice a week initially and, if stable, testing can be spaced to once a week
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver enzymes (alanine aminotransferase and aspartate aminotransferase) twice a week initially and, if stable, testing can be spaced to once a week
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Amphotericin B lipid formulations
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest conventional amphotericin B (ie,
         <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">
          amphotericin B deoxycholate
         </a>
         ) over the lipid-based amphotericin B formulations. The lipid formulations do not appear to be superior to the less expensive amphotericin B deoxycholate. They are typically reserved for patients who develop intolerant infusion-related reactions or renal dysfunction during standard amphotericin B administration. The lipid formulations should
         <strong>
          not
         </strong>
         be used in patients with
         <em>
          Candida
         </em>
         urinary tract infections (UTIs).
        </p>
        <p>
         Lipid-based amphotericin B formulations have the ability to deliver a higher dose of medication with lower levels of toxicity but are significantly more expensive than standard amphotericin B. Data on the use of these agents in neonates are limited to case reports and case series [
         <a href="#rid23">
          23-27
         </a>
         ]. Most reports show that lipid-based amphotericin B preparations successfully treated neonates with candidemia and were not associated with any major adverse effects. However, in a multicenter retrospective review of 730 infants with positive blood, urine, or cerebrospinal fluid (CSF) cultures for
         <em>
          Candida
         </em>
         species, multivariate analysis showed higher mortality for infants receiving amphotericin B lipid products compared with infants receiving
         <a class="drug drug_pediatric" data-topicid="12647" href="/z/d/drug information/12647.html" rel="external">
          amphotericin B deoxycholate
         </a>
         (odds ratio 1.96, 95% CI 1.16-3.33) or
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         (odds ratio 2.39, 95% CI 1.18-4.83) [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Fluconazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          Fluconazole
         </a>
         , a first-generation triazole, is an alternative to amphotericin B in some infants, if the isolate is susceptible. Fluconazole has several advantages:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excellent therapeutic levels throughout the body including the CSF [
         <a href="#rid29">
          29
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excellent agent for the treatment of
         <em>
          Candida
         </em>
         UTI because it is excreted unchanged in high concentrations into the urine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excellent bioavailability when taken orally, potentially reducing the need for IV administration
        </p>
        <p>
        </p>
        <p>
         The major disadvantage of this agent is the emergence of fluconazole-resistant
         <em>
          Candida
         </em>
         species, such as
         <em>
          C
         </em>
         .
         <em>
          krusei
         </em>
         ,
         <em>
          C
         </em>
         .
         <em>
          glabrata
         </em>
         , and
         <em>
          Candida
         </em>
         <em>
          parapsilosis
         </em>
         [
         <a href="#rid30">
          30
         </a>
         ]. The use of
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         prophylaxis to reduce
         <em>
          Candida
         </em>
         infections may also be a contributing factor to fluconazole resistance. (See
         <a class="medical medical_review" href="/z/d/html/5042.html" rel="external">
          "Prevention of Candida infection in neonates"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         .)
        </p>
        <p>
         Thus,
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         should not be used as the agent for initial treatment of an infant with candidemia or suspected candidemia. It should be given only after identifying the
         <em>
          Candida
         </em>
         species and determining that the organism is sensitive to fluconazole. This is especially important if prior fluconazole prophylaxis has been given to the infant.
        </p>
        <p>
         For treatment of systemic candidiasis,
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         dosing for susceptible isolates consists of a an initial loading dose of 25 mg/kg IV followed by 12 mg/kg per dose IV once daily [
         <a href="#rid2">
          2,31
         </a>
         ]. IV administration is generally preferred over oral for the treatment of invasive infections. Oral fluconazole may be appropriate for treatment of isolated uncomplicated UTI and for mucocutaneous candidiasis, including congenital cutaneous candidiasis (CCC) in term infants who are clinically stable and tolerating full enteral feeding.
        </p>
        <p>
         The dosing interval may be extended to 48 hours in extremely premature infants with impaired renal clearance. One small study involving only eight infants demonstrated that administering an initial loading dose achieved therapeutic levels more rapidly than the standard regimen without a loading dose [
         <a href="#rid32">
          32
         </a>
         ]. However, larger studies are needed to confirm that this is a safe and more effective dosing regimen before it can be recommended as standard practice. Centers should consider the minimum inhibitory concentration range of the isolates of colonizing
         <em>
          Candida
         </em>
         species found in their unit when deciding on the dosing regimen.
        </p>
        <p>
         Lower doses (3 to 6 mg/kg twice weekly) are typically used for antifungal prophylaxis in preterm infants when such prophylaxis is warranted. Antifungal prophylaxis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5042.html" rel="external">
          "Prevention of Candida infection in neonates", section on 'Antifungal prophylaxis'
         </a>
         .)
        </p>
        <p>
         The efficacy of
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         for treatment of invasive candidiasis is supported by two small prospective studies [
         <a href="#rid33">
          33,34
         </a>
         ]. In a randomized trial in 23 infants with proven fungal septicemia randomly assigned fluconazole (IV or enterally) or amphotericin B, infants in the fluconazole group required fewer days of IV therapy [
         <a href="#rid34">
          34
         </a>
         ]. However, mortality rates were high in both groups (3 of 12 patients in the fluconazole group versus 5 of 11 patients in the amphotericin B group). Patients who received fluconazole appeared to have less hepatotoxicity with lower serum bilirubin and alkaline phosphatase concentrations [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         Second-generation triazoles, such as
         <a class="drug drug_pediatric" data-topicid="12885" href="/z/d/drug information/12885.html" rel="external">
          voriconazole
         </a>
         , have been developed with a broader spectrum of activity and increased potency. In adult trials, they are effective in fluconazole-resistant species, but there are no comparable data in neonates. (See
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Flucytosine
         </span>
         <span class="headingEndMark">
          —
         </span>
         In neonates, use of
         <a class="drug drug_pediatric" data-topicid="13304" href="/z/d/drug information/13304.html" rel="external">
          flucytosine
         </a>
         is mostly limited to treatment of CNS infections that do not respond to monotherapy with amphotericin B. In this setting, flucytosine is used in combination with amphotericin B because it has excellent penetration into the CSF and is synergistic with amphotericin B [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Drawbacks of this agent in neonates include its considerable side effect profile, rapid development of resistance when used as monotherapy, and lack of availability of a parenteral formulation, thus limiting its use in critically ill neonates. (See
         <a class="medical medical_review" href="/z/d/html/472.html" rel="external">
          "Pharmacology of flucytosine (5-FC)", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         The oral dose is 50 to 150 mg/kg per day divided into four doses at six-hour intervals. It is critical to monitor blood levels of
         <a class="drug drug_pediatric" data-topicid="13304" href="/z/d/drug information/13304.html" rel="external">
          flucytosine
         </a>
         to avoid bone marrow toxicity. Peak plasma concentrations obtained 60 to 120 minutes after administration should be maintained between 40 and 60 mcg/mL, and trough levels obtained prior to the next dose should be less than 25 mcg/mL. Bone marrow suppression is increased with sustained levels greater than 100 mcg/mL.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Echinocandins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins, which include
         <a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="130086" href="/z/d/drug information/130086.html" rel="external">
          anidulafungin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">
          micafungin
         </a>
         , are not routinely used in neonates. They may be considered in infants for whom the use of
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         and amphotericin is precluded because of drug toxicity or antifungal resistance [
         <a href="#rid35">
          35
         </a>
         ]. These agents appear to be well tolerated with a minimum of adverse effects in adult patients, but data in neonates are limited. Resistance to this class of antifungal agents is uncommon. Echinocandins appear to be a promising class of antifungal agents in the treatment of neonatal candidemia. Some experts have proposed using micafungin as a first-line antifungal agent in preterm neonates [
         <a href="#rid8">
          8
         </a>
         ]; however, further data on their efficacy, safety, and dosing regimen in neonates are needed before echinocandins can be recommended for routine use.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Micafungin – The efficacy and safety of
         <a class="drug drug_pediatric" data-topicid="12713" href="/z/d/drug information/12713.html" rel="external">
          micafungin
         </a>
         in neonates are supported by observational data and small clinical trials [
         <a href="#rid36">
          36-43
         </a>
         ]. In a systematic review of nine clinical trials evaluating the safety and efficacy of micafungin in infants &lt;2 years (116 patients, 48 percent preterm infants), micafungin had good efficacy (73 percent treatment success among patients with invasive candidiasis) and was well tolerated without serious side effects [
         <a href="#rid40">
          40
         </a>
         ]. In a subsequent clinical trial in 30 infants (most were ≤4 weeks old) with invasive candidiasis randomized to treatment with micafungin or amphotericin B, the rate of complete or partial clinical response after one week was similar in both groups (61 and 70 percent, respectively). The rate of treatment-associated adverse events was also similar in both groups (55 and 50 percent, respectively), with transient anemia and thrombocytopenia being the most common.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Caspofungin – A small multicenter randomized trial compared
         <a class="drug drug_pediatric" data-topicid="12914" href="/z/d/drug information/12914.html" rel="external">
          caspofungin
         </a>
         with amphotericin B in 47 neonates and young infants with invasive candida infection [
         <a href="#rid44">
          44
         </a>
         ]. At two weeks, the proportion of infants who were alive and free of infection was similar in both groups (71 versus 69 percent); adverse events occurred less commonly in the caspofungin group (85 versus 100 percent). However, the trial was stopped early due to low enrollment and, as such, it may have been inadequately powered to detect important differences in outcomes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          OUTCOME
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of preterm infants with invasive candidal infections is guarded, with reported mortality rates of approximately 20 to 40 percent among extremely low birth weight infants (ELBW; birth weight &lt;1000 g) [
         <a href="#rid45">
          45-52
         </a>
         ]. Survivors of neonatal candidemia, especially in those with central nervous system (CNS) involvement, are at risk of long-term neurodevelopmental impairment [
         <a href="#rid45">
          45-48,53,54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4036286583">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preventive measures to reduce the risk of developing candidal infections include efforts to reduce
         <em>
          Candida
         </em>
         cross-transmission and risk factors associated with fungal infections, as well as the use of prophylactic antifungal agents. These issues are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5042.html" rel="external">
          "Prevention of Candida infection in neonates"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3661789289">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/104270.html" rel="external">
          "Society guideline links: Candidiasis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Noninvasive mucocutaneous candidiasis
         </strong>
         – For most neonates with noninvasive mucocutaneous candidiasis (ie, thrush, diaper dermatitis), we suggest topical antifungal therapy rather than systemic therapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). The choice of therapy is as follows (see
         <a class="local">
          'Mucocutaneous candidiasis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For neonates with oral candidiasis (thrush), we suggest treatment with oral
         <a class="drug drug_pediatric" data-topicid="12654" href="/z/d/drug information/12654.html" rel="external">
          nystatin
         </a>
         rather than other topical agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Nystatin is administered as an oral suspension (100,000 units/mL) at a dose of 0.5 mL to each side of the mouth four times a day between feeds for 5 to 10 days. Oral
         <a class="drug drug_pediatric" data-topicid="16825" href="/z/d/drug information/16825.html" rel="external">
          miconazole
         </a>
         gel is an alternative option, but it has a high rate of side effects in preterm infants. No specific treatment is a reasonable alternative in healthy term infants who lack symptoms, are feeding well, and are at low risk of invasive candidiasis. (See
         <a class="local">
          'Oral candidiasis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For neonates with diaper dermatitis, we suggest treatment with topical
         <a class="drug drug_pediatric" data-topicid="12654" href="/z/d/drug information/12654.html" rel="external">
          nystatin
         </a>
         or azole cream (eg,
         <a class="drug drug_pediatric" data-topicid="16825" href="/z/d/drug information/16825.html" rel="external">
          miconazole
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13173" href="/z/d/drug information/13173.html" rel="external">
          clotrimazole
         </a>
         cream) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Nystatin usually is effective and is generally the least expensive option. (See
         <a class="local">
          'Diaper dermatitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Systemic antifungal agents are used for mucocutaneous infections only if the infection is refractory to topical therapy or if there is high risk of systemic infection (eg, congenital candidiasis, invasive dermatitis). (See
         <a class="local">
          'High risk of systemic infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Invasive
         </strong>
         <strong>
          <em>
           Candida
          </em>
         </strong>
         <strong>
          infections
         </strong>
         – Management of neonates with invasive
         <em>
          Candida
         </em>
         infections, including bloodstream, urinary tract, central nervous system (CNS), and/or other invasive focal infection, involves the following components:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evaluation to assess the extent of dissemination (see
         <a class="local">
          'Evaluation for extent of dissemination'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Removal of any source of infection (eg, central venous catheter [CVC], urinary catheter) (see
         <a class="local">
          'Catheter-associated candidemia'
         </a>
         above and
         <a class="local">
          'Urinary tract infection'
         </a>
         above and
         <a class="local">
          'Persistent infection'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administration of systemic antifungal agents (see
         <a class="local">
          'Systemic antifungal agents'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of systemic antifungal agent
         </strong>
         – For most neonates with invasive
         <em>
          Candida
         </em>
         infection, we suggest amphotericin B for initial therapy rather than other systemic antifungal agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The dose of amphotericin B is 1 mg/kg given intravenously (IV) once daily. Once results of susceptibility testing are available, therapy should be modified if the organism is resistant to amphotericin B. IV
         <a class="drug drug_pediatric" data-topicid="13303" href="/z/d/drug information/13303.html" rel="external">
          fluconazole
         </a>
         is a reasonable alternative to amphotericin B if the isolate is susceptible. (See
         <a class="local">
          'Invasive infection'
         </a>
         above and
         <a class="local">
          'Amphotericin B'
         </a>
         above and
         <a class="local">
          'Therapy based on susceptibility'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of therapy
         </strong>
         – The duration of therapy depends on the type of infection, as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Uncomplicated candidemia
         </strong>
         – For neonates with candidemia (including CVC-associated candidemia) who lack evidence of metastatic foci of infection, treatment is continued for a minimum of 14 days after the first sterile blood culture and resolution of signs attributable to candidemia. If a CVC is present, it should be removed as soon as possible. (See
         <a class="local">
          'Catheter-associated candidemia'
         </a>
         above and
         <a class="local">
          'Disseminated disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Uncomplicated urinary tract infection (UTI)
         </strong>
         – For neonates with candidal UTI and no evidence of fungal abscess or mass on imaging, treatment is continued for 10 to 14 days. The urinary catheter, if present, should be removed as soon as possible. (See
         <a class="local">
          'Urinary tract infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CNS infection
         </strong>
         – Treatment continues for a minimum of three weeks and should be continued until all clinical signs, cerebrospinal fluid (CSF) abnormalities, and radiographic abnormalities (if present) have resolved. CNS devices (eg, shunts and ventriculostomy drains), if present, should be removed whenever possible. If the CSF does not become sterile within a few days or if the patient's clinical status deteriorates despite treatment with amphotericin B monotherapy,
         <a class="drug drug_pediatric" data-topicid="13304" href="/z/d/drug information/13304.html" rel="external">
          flucytosine
         </a>
         (25 mg/kg per dose given orally every six hours) can be added to the regimen. (See
         <a class="local">
          'Central nervous system infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Disseminated disease with focal infection sites
         </strong>
         – Candidemia associated with metastatic foci of infection (eg, endocarditis, renal fungal masses) is often persistent and/or difficult to eradicate. The duration of therapy is individualized based upon sterilization of blood cultures, resolution of clinical signs, and resolution imaging findings. Prolonged therapy is generally warranted. Surgical removal of the infected foci may also be necessary in some cases. (See
         <a class="local">
          'Disseminated disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring during therapy
         </strong>
         – Infants receiving amphotericin B should have serial monitoring with the following laboratory studies (see
         <a class="local">
          'Monitoring'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum electrolytes (including potassium and magnesium) daily or every other day
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum creatinine daily or every other day initially and, if stable, testing can be spaced to twice weekly
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count with differential and platelet count twice a week initially and, if stable, testing can be spaced to once a week
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Liver enzymes (alanine aminotransferase and aspartate aminotransferase) twice a week initially and, if stable, testing can be spaced to once a week
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The prognosis of invasive candidal infections in preterm infants is guarded, with reported mortality rates of approximately 40 in extremely low birth weight (ELBW) infants. (See
         <a class="local">
          'Outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Candidiasis. In: Red Book: 2021–2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.246.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goins RA, Ascher D, Waecker N, et al. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr Infect Dis J 2002; 21:1165.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence. Postnatal care up to 8 weeks after birth: Clinical guideline. 2015. Available at: https://www.nice.org.uk/guidance/CG37/chapter/1-Recommendations (Accessed on October 27, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe JE. Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal. Pediatr Infect Dis J 1997; 16:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darmstadt GL, Dinulos JG, Miller Z. Congenital cutaneous candidiasis: clinical presentation, pathogenesis, and management guidelines. Pediatrics 2000; 105:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman DA, Coggins SA, Zanelli SA, Weitkamp JH. Congenital Cutaneous Candidiasis: Prompt Systemic Treatment Is Associated With Improved Outcomes in Neonates. Clin Infect Dis 2017; 64:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manzoni P, Mostert M, Castagnola E. Update on the management of Candida infections in preterm neonates. Arch Dis Child Fetal Neonatal Ed 2015; 100:F454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karlowicz MG, Hashimoto LN, Kelly RE Jr, Buescher ES. Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics 2000; 106:E63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin DK Jr, Fisher RG, McKinney RE Jr, Benjamin DK. Candidal mycetoma in the neonatal kidney. Pediatrics 1999; 104:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman LH, Stringer DA, St Onge O, et al. An assessment of sonography in the diagnosis and management of neonatal renal candidiasis. Clin Radiol 1989; 40:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010; 26:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckstein CW, Kass EJ. Anuria in a newborn secondary to bilateral ureteropelvic fungus balls. J Urol 1982; 127:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan MY. Anuria from candida pyelonephritis and obstructing fungal balls. Urology 1983; 21:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson DE, Base JL, Thompson TR, et al. Candida septicemia and right atrial mass secondary to umbilical vein catheterization. Am J Dis Child 1981; 135:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faix RG, Feick HJ, Frommelt P, Snider AR. Successful medical treatment of Candida parapsilosis endocarditis in a premature infant. Am J Perinatol 1990; 7:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hundalani S, Pammi M. Invasive fungal infections in newborns and current management strategies. Expert Rev Anti Infect Ther 2013; 11:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990; 9:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Autmizguine J, Tan S, Cohen-Wolkowiez M, et al. Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. Pediatr Infect Dis J 2018; 37:923.
          </a>
         </li>
         <li class="breakAll">
          Bendel CM. Candidiasis. In: Infectious diseases of the fetus and newborn infant, 6th, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.1107.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J 2009; 28:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999; 18:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998; 17:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juster-Reicher A, Flidel-Rimon O, Amitay M, et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003; 22:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000; 28:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitkamp JH, Poets CF, Sievers R, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998; 26:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ascher SB, Smith PB, Watt K, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J 2012; 31:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxén H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993; 54:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneshnia F, de Almeida Júnior JN, Ilkit M, et al. Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. Lancet Microbe 2023; 4:e470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wade KC, Benjamin DK Jr, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009; 28:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piper L, Smith PB, Hornik CP, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J 2011; 30:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wainer S, Cooper PA, Gouws H, Akierman A. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J 1997; 16:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996; 15:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol 2009; 29:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith PB, Steinbach WJ, Cotten CM, et al. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol 2007; 27:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005; 25:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manzoni P, Wu C, Tweddle L, Roilides E. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J 2014; 33:e291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manzoni P, Benjamin DK Jr, Franco C, et al. Echinocandins for the nursery: an update. Curr Drug Metab 2013; 14:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sáez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009; 53:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin DK Jr, Kaufman DA, Hope WW, et al. A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. Pediatr Infect Dis J 2018; 37:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim J, Nakwa FL, Araujo Motta F, et al. A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age. J Antimicrob Chemother 2020; 75:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams-Chapman I, Bann CM, Das A, et al. Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. J Pediatr 2013; 163:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton M, O'Brien K, Robinson JL, et al. Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. BMC Infect Dis 2014; 14:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006; 117:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Haan TR, Beckers L, de Jonge RC, et al. Neonatal gram negative and Candida sepsis survival and neurodevelopmental outcome at the corrected age of 24 months. PLoS One 2013; 8:e59214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117:1680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin DK Jr, Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010; 126:e865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xia H, Wu H, Xia S, et al. Invasive Candidiasis in preterm neonates in China: a retrospective study from 11 NICUS during 2009-2011. Pediatr Infect Dis J 2014; 33:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000; 19:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brumbaugh JE, Bell EF, Do BT, et al. Incidence of and Neurodevelopmental Outcomes After Late-Onset Meningitis Among Children Born Extremely Preterm. JAMA Netw Open 2022; 5:e2245826.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5029 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12506950" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12506950" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9306485" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10654973" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Congenital cutaneous candidiasis: clinical presentation, pathogenesis, and management guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28158439" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Congenital Cutaneous Candidiasis: Prompt Systemic Treatment Is Associated With Improved Outcomes in Neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25605617" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Update on the management of Candida infections in preterm neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11061800" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Should central venous catheters be removed as soon as candidemia is detected in neonates?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10545558" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Candidal mycetoma in the neonatal kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2689053" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : An assessment of sonography in the diagnosis and management of neonatal renal candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20513206" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Challenging issues in neonatal candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7057477" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Anuria in a newborn secondary to bilateral ureteropelvic fungus balls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6836840" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Anuria from candida pyelonephritis and obstructing fungal balls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6782858" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Candida septicemia and right atrial mass secondary to umbilical vein catheterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2372336" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Successful medical treatment of Candida parapsilosis endocarditis in a premature infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23829639" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Invasive fungal infections in newborns and current management strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2329429" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2300413" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29369937" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29369937" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935267" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Nephrotoxicity associated with amphotericin B deoxycholate in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10462340" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9493812" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Liposomal amphotericin B treatment for neonatal fungal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13680398" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10961528" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9505173" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22189522" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Antifungal therapy and outcomes in infants with invasive Candida infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8375121" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37121240" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19593252" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21085048" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Fluconazole loading dose pharmacokinetics and safety in infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9271038" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prospective study of fluconazole therapy in systemic neonatal fungal infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8970221" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19776753" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17262048" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Caspofungin for the treatment of azole resistant candidemia in a premature infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16222348" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Experience with caspofungin in the treatment of persistent fungemia in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15626944" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Caspofungin therapy of neonates with invasive candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17133155" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24892849" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22935065" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Echinocandins for the nursery: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19075070" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29596222" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31586424" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23726546" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Neurodevelopmental outcome of extremely low birth weight infants with Candida infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24924877" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16396864" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23527140" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Neonatal gram negative and Candida sepsis survival and neurodevelopmental outcome at the corrected age of 24 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651324" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876174" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Neonatal candidiasis: epidemiology, risk factors, and clinical judgment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10783022" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24153006" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Invasive Candidiasis in preterm neonates in China: a retrospective study from 11 NICUS during 2009-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10877162" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36480199" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Incidence of and Neurodevelopmental Outcomes After Late-Onset Meningitis Among Children Born Extremely Preterm.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
